Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial

  • Protalix BioTherapeutics Inc PLX and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have announced topline data from the BALANCE Phase 3 trial evaluating pegunigalsidase alfa (PRX–102) for Fabry disease. 
  • PRX–102 is a PEGylated enzyme substitute therapy (ERT) 
  • The study met its prespecified primary endpoint and demonstrated that PRX-102 was statistically non-inferior to agalsidase beta.
  • The median of the estimated glomerular filtration rate (eGFR) slope in the PRX-102 arm was –2.514 mL/min/1.73 m2/year (–3.788, –1.240) and –2.155 mL/min/1.73 m2/year (–3.805, –0.505) in the agalsidase beta arm. 
  • Related: Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease.
  • Forty-seven (90.4%) patients in the PRX–102 arm experienced at least one adverse event than 24 (96.0%) in the agalsidase beta arm. 
  • Treatment-related adverse events were reported for 21 (40.4%) patients in the PRX–102 arm compared to 11 (44.0%) in the agalsidase beta arm. 
  • The infusion-related reactions adjusted to 100 infusions are 0.5 for the PRX–102 arm and 3.9 for the agalsidase beta arm.
  • Price Action: PLX shares are up 81.40% at $1.91 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!